: Altimmune’s stock pops as analysts see obesity-drug partnership potential

Altimmune shares have jumped this week as analysts see potential for the company to find a partner for its experimental weight-loss drug.

Previous post Mark Hulbert: How watching the Republican debates can make you a better investor
Next post : The great Hanukkah debate: Which night is best to give out the gifts?